The UK and US have hammered out a major trade agreement that will guarantee zero import taxes on UK drug exports going into the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has agreed to boost spending on drugs through the public health system. This commitment guarantees that tariffs on these crucial exports will be held at zero for a timeframe of the next three years.
This development follows earlier warnings to dramatically increase import taxes on branded drug imports, with potential rates discussed reaching 100%.
"This deal with the United Kingdom strengthens the global environment for cutting-edge drugs and establishes much-needed balance to transatlantic drug exports," a release noted.
Trade Impact
Pharmaceuticals represent one of the the United Kingdom's largest export categories to the United States, which is by far the biggest buyer for large British pharmaceutical firms.
Export figures show that in the 12 months to the end of September, the UK shipped pharmaceutical products totaling over eleven billion pounds to the US. This value accounted for 17.4% of all goods exports in that span.
"This agreement secures jobs, boosts capital expenditure and facilitates the UK to establish itself as a global hub for life sciences," a government official stated.
Detailed UK Commitments
The agreement involves several key commitments from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it judges new medicines to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a goal to increase total public funding on medicines from 0.3% of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The sum manufacturers must return to the NHS to control costs will be limited at 15%. Last year, rebates topped twenty percent.
Industry Background
The pact takes place against a ongoing dispute between the sector and the UK government over spending levels and NHS adoption.
These tensions were intensified by claims that US patients were charged several times more for the same drugs than people in the UK and Europe.
Recently, several major manufacturing plans in the UK have been halted or cancelled, while major funding commitments have been announced toward projects in the United States.
The Science Minister stated that the NHS needed to invest a greater share on treatments, noting that its expenditure on drugs had decreased as a share of its total funding over the previous ten-year period.
